Methylprednisolone Dialyzability
Methylprednisolone is dialyzable during hemodialysis, with a significant dialysance of approximately 18.4 ml/min, but dose adjustment is generally not required in most clinical situations because the drug's pharmacokinetics remain unchanged in chronic renal failure. 1, 2
Dialyzability Evidence
Hemodialysis removes methylprednisolone with a measured dialysance of 18.4 ± 6.1 ml/min and a half-life of 149 ± 26 minutes during dialysis. 1
Despite this measurable removal, the total clearance and volume of distribution of methylprednisolone remain unchanged in chronic renal failure patients (clearance ~280 ml/h/kg, volume of distribution ~1.1 L/kg). 2
The drug's pharmacodynamics (IC50 for cortisol suppression, T-cell and basophil recirculation) are also unaltered in renal failure, meaning therapeutic responsiveness is preserved. 2
Dosing Recommendations
Standard dosing should be used without adjustment for dialysis patients in most clinical scenarios. 3, 2
For high-dose therapy: 30 mg/kg IV over at least 30 minutes, repeated every 4-6 hours for up to 48 hours as needed. 3
For pulse therapy in lupus nephritis: 500-2500 mg total dose (depending on disease severity), followed by oral prednisone 0.3-0.5 mg/kg/day, tapered to ≤7.5 mg/day by 3-6 months. 4
For standard indications: 10-40 mg IV depending on the specific disease entity. 3
Clinical Context for Dose Adjustment
The only situation requiring potential dose adjustment is when hemodialysis is performed during active high-dose methylprednisolone therapy for life-threatening conditions where maintaining peak drug levels is critical. 1
In such cases, consider administering the dose after dialysis to avoid removal during the dialysis session. 5
For routine maintenance therapy or pulse dosing regimens, the dialyzable fraction is clinically insignificant because the drug's overall clearance and therapeutic effect remain intact. 2
Important Caveats
Methylprednisolone is NOT significantly removed by peritoneal dialysis, so no special considerations apply for PD patients. 6
The prodrug methylprednisolone sodium succinate has 40% reduced clearance in chronic renal failure, but this does not affect the active methylprednisolone pharmacokinetics. 2
Continuous renal replacement therapy (CRRT) shows variable extraction of methylprednisolone (mean plasma recovery 0.4-49%), and coadministration with other drugs can significantly alter extraction, potentially requiring dosing adjustments in CRRT patients. 7